Skip to content
Clinical Trials – home

Catharina Ziekenhuis Stichting

Verified siteinfo

The Netherlands Michelangelolaan 2, 5623 EJ Eindhoven, The Netherlands

  • 68 trials recruiting
  • Arteriosclerosis · Gastric cancer · Prostate cancer
  • Adults and children

About Specializations

Catharina Ziekenhuis Stichting in Eindhoven, The Netherlands specialises in clinical trials of conditions such as Arteriosclerosis, Gastric cancer, Prostate cancer, Rectal cancer, and other specialisations. This site conducts important research.

Main research areas of the site

Cardiovascular Diseases

At Catharina Ziekenhuis Stichting in Eindhoven, a major focus is cardiovascular disease research, with studies addressing atherosclerotic cardiovascular disease, acute coronary syndrome, atrial fibrillation, and myocardial infarction. The trials are mainly designed to test new ways to prevent heart attacks and stroke, reduce clot-related complications, and improve long-term cardiovascular outcomes.

  • Preventing major adverse cardiovascular events in people at high risk
  • Reducing stroke and systemic embolism in atrial fibrillation
  • Evaluating safer and more effective antithrombotic treatment strategies

This work reflects a strong interest in both heart and vascular medicine, with emphasis on better protection against recurrent events and treatment-related bleeding risk.

Oncology and Hematologic Malignancies

The site also has an active program in oncology and hematologic cancers, including prostate cancer, colorectal cancer, gastric cancer, esophageal cancer, cervical cancer, endometrial cancer, pleural mesothelioma, diffuse large B-cell lymphoma, and leukemia. These trials are aimed at improving survival, strengthening disease control, and refining treatment approaches for both solid tumors and blood cancers.

  • Testing new combinations for advanced and high-risk cancers
  • Improving outcomes after surgery or chemoradiation
  • Exploring more effective options for relapsed or difficult-to-treat blood cancers

The research portfolio includes both treatment intensification and treatment optimization, showing a broad effort to improve cancer care across several disease types.

Women’s Health, Fertility, and Pregnancy-Related Research

In Obstetrics & Gynaecology, the research includes female urogenital diseases, pregnancy complications, subfertility, and recurrent miscarriage. Studies at the Catharina Ziekenhuis Stichting are focused on preserving fertility, supporting early pregnancy, and improving outcomes for women with gynecologic cancers and reproductive health concerns.

  • Assessing fertility-sparing approaches in cervical cancer
  • Improving live birth rates in subfertility treatment
  • Evaluating therapies for unexplained recurrent miscarriages

This area combines cancer care with reproductive medicine, highlighting a patient-centered effort to protect both health and future fertility.

Digestive, Respiratory, and Inflammatory Conditions

The trial portfolio also covers digestive system diseases, respiratory tract diseases, and immune-related conditions. Research topics include acute pancreatitis, esophageal surgery-related infections, and pulmonary sarcoidosis, with studies designed to reduce complications, improve recovery, and better control inflammatory disease activity.

  • Lowering organ failure and mortality in acute pancreatitis
  • Preventing infectious complications after esophagectomy
  • Assessing new treatment options for pulmonary sarcoidosis

This research shows a practical focus on improving supportive care and treatment effectiveness in complex medical conditions that affect the digestive and respiratory systems.

Reproductive and Urinary Physiology

The site’s studies in reproductive and urinary physiological phenomena include investigations into treatment strategies that may preserve organ function and support quality of life, especially in patients with prostate cancer and gynecologic malignancies. These trials aim to refine treatment timing and intensity while balancing disease control with functional outcomes.

  • Exploring treatment strategies that may reduce long-term toxicity
  • Supporting function preservation alongside cancer control
  • Evaluating approaches that may improve patient quality of life

This field adds an important functional dimension to the broader oncology program, linking cancer treatment with everyday well-being.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Michelangelolaan 25623 EJ EindhovenThe Netherlands
Recruiting now
68 trials
Conditions studied
107
Partner status
Verified site

More sites in EindhovenThe Netherlands

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

141 clinical trials

Obesity+2

Recruiting

Effect of zenagamtide on major adverse cardiovascular events in overweight or obese adults with established atherosclerotic cardiovascular disease

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Sponsor:Novo Nordisk A/S

Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim Espana S.A.

Cardiac failure

Recruiting

Study on BI 690517 and Empagliflozin for Patients with Heart Failure and Preserved Ejection Fraction

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim International GmbH

Study on Selatogrel for Preventing Heart Attack in Patients with Recent Heart Attack History

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Selatogrel
  • Sponsor:Viatris Innovation GmbH

Study on Clazakizumab for Heart Disease in Adults with End-Stage Kidney Disease on Dialysis

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Clazakizumab
  • Sponsor:CSL Behring LLC

Ramantamig (JNJ-79635322) with drug combination versus standard therapy in newly diagnosed multiple myeloma patients not eligible for stem cell transplant

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Randomized Study of INCB161734 Plus Standard Chemotherapy Drug Combination in Untreated KRAS G12D Metastatic Pancreatic Ductal Adenocarcinoma Patients

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Incyte Corp.

Evaluation of pembrolizumab and bevacizumab in patients with metastatic cervical cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Universitair Medisch Centrum Groningen

A study to evaluate the effectiveness of methotrexate in preventing the recurrence of dermatological vulvar intraepithelial neoplasia in women with lichen sclerosus.

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Methotrexate
  • Sponsor:Amsterdam UMC Stichting

Cardiac failure+1

Recruiting

Study of Zenagamtide (NNC0487-0111) versus placebo in patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Sponsor:Novo Nordisk A/S

Study of pembrolizumab, capecitabine, or olaparib in patients with early-stage triple negative breast cancer and remaining disease after initial treatment

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Gastric cancer

Recruiting

A study of irinotecan and a drug combination for patients with gastric cancer or gastroesophageal junction cancer undergoing surgery.

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Irinotecan Hydrochloride Trihydrate
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.